Clinical trial
A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)
NCT07185997 is registered in ClinicalTrials.gov with ArriVent BioPharma, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)
- Lead sponsor
- ArriVent BioPharma, Inc.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- December 17, 2025
- Completion date
- December 31, 2030
- Enrollment
- 480 (estimated)
- Sites
- 139
Conditions
As the registry lists them; a condition with its own page is linked.
advanced non-small-cell lung cancer, egfr p-loop and alpha c-helix compressing, egfr pacc, egfr uncommon mutations, metastatic non-small-cell lung cancer, non-small-cell lung cancer